2. Academic Validation
  3. Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy

Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy

  • Pharmacol Ther. 2021 Jun;222:107790. doi: 10.1016/j.pharmthera.2020.107790.
Gregory P Takacs 1,  Joseph A Flores-Toro 1,  Jeffrey K Harrison 2
Affiliations

Affiliations

  • 1 Department of Pharmacology & Therapeutics, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
  • 2 Department of Pharmacology & Therapeutics, College of Medicine, University of Florida, Gainesville, FL 32610, USA. Electronic address: [email protected].
PMID: 33316289 DOI: 10.1016/j.pharmthera.2020.107790
Abstract

Chemokines are a large subfamily of cytokines known for their ability to facilitate cell migration, most notably leukocytes, throughout the body. Chemokines are necessary for a functioning immune system in both health and disease and have received considerable attention for their roles in orchestrating temporal-spatial regulation of immune cell populations in Cancer. Gliomas comprise a group of common central nervous system (CNS) primary tumors that are extremely challenging to treat. Immunotherapy approaches for highly malignant brain tumors offer an exciting new avenue for therapeutic intervention but so far, have seen limited successful clinical outcomes. Herein we focus on important chemokine/Chemokine Receptor systems in the regulation of pro- and anti-tumor mechanisms, highlighting potential therapeutic advantages of modulating these systems in malignant gliomas and other cancers.

Keywords

Chemokine; Glioblastoma; Immunotherapy; MDSC; Microglia; Tumor microenvironment.

Figures
Products